Picoplatin

Picoplatin
Names
	IUPAC name azane; 2-methylpyridine; platinum(2+); dichloride
Identifiers
CAS Number	181630-15-9 ;
3D model (JSmol)	ionic form: Interactive image; coordination form: Interactive image;
ChemSpider	154428 ;
ECHA InfoCard	100.205.233
PubChem CID	177358;
UNII	B5TAN0L720 ;
CompTox Dashboard (EPA)	DTXSID10939458 ;
	InChI InChI=1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;21H;1H3;/q;;;;+2/p-2 Key: IIMIOEBMYPRQGU-UHFFFAOYSA-L ; InChI=1/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;21H;1H3;/q;;;;+2/p-2 Key: IIMIOEBMYPRQGU-NUQVWONBAG;
	SMILES ionic form: Cc1ccccn1.N.[Cl-].[Cl-].[Pt+2]; coordination form: Cl[Pt-2](Cl)([NH3+])[n+]1ccccc1C;
Properties
Chemical formula	C6H10Cl2N2Pt
Molar mass	376.14 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.^[1]

In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.^[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.^[3] Hopes are now pinned on its use for metastatic colorectal cancer.^[4]

References

^ Wheate, Nial J. (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials" (PDF). Dalton Transactions. 39 (35): 8113–8127. doi:10.1039/C0DT00292E. hdl:2123/14271. PMID 20593091.
^ Picoplatin Clinical Results, Poniard Pharmaceuticals
^ Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009
^ http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] Wheate, Nial J. (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials" (PDF). Dalton Transactions. 39 (35): 8113–8127. doi:10.1039/C0DT00292E. hdl:2123/14271. PMID 20593091.

[2] Picoplatin Clinical Results, Poniard Pharmaceuticals

[3] Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009

[4] ttp://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009

[1]

[2]

[3]

[4]